Want to see SE:ONCOZ full AI Analyst Report?
ONCOZ Stock Chart & Stats
kr5.51
kr0.40(6.64%)
At close: 4:00 PM EST
kr5.51
kr0.40(6.64%)
Day’s Range― - ―
52-Week Rangekr4.52 - kr10.28
Previous CloseN/A
Volume9.67K
Average Volume (3M)35.93K
Market Cap
kr92.30M
Enterprise Valuekr79.68
Total Cash (Recent Filing)kr935.00K
Total Debt (Recent Filing)kr7.50M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding14,048,068
10 Day Avg. Volume29,683
30 Day Avg. Volume35,930
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio-6.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1
Revenue Forecast (FY)kr10.00M
Bulls Say, Bears Say
Bulls Say
Targeted Therapy For Oral MucositisOncoZenge focuses on a defined supportive-care indication (oral mucositis), a recurrent and clinically important problem in oncology. A focused, clinical-stage product addressing an unmet pain need can generate predictable, recurring demand in oncology care and attract partners seeking niche supportive-care assets.
Positive Gross Profit In TTMReported positive gross profit, even if small, indicates underlying unit economics for the product may be viable once scale is achieved. This suggests the product can generate margin per sale and that future commercialization could more directly offset operating costs than R&D-only profiles with zero gross margin.
Flexible Commercialization/partnering ModelA mixed strategy—direct commercialization or out-licensing—provides durable strategic optionality. Partnering can accelerate market access and shift capital burden to larger pharma, while direct sales preserve upside. This flexibility reduces single-path execution risk over the medium term.
Bears Say
Heavy Cash Burn & Minimal RevenuePersistent, large operating cash outflows relative to negligible revenue create a structural funding need. Over 2–6 months this forces dependence on external financing, increasing dilution or debt risk and constraining the company’s ability to fund trials, regulatory work, or commercial rollout without partner funding.
Extremely High LeverageA sharp shift to debt and a very thin equity base materially raise solvency and refinancing risk. High leverage limits flexibility to raise additional capital on favorable terms, increases fixed cash obligations for interest and principal, and elevates bankruptcy risk if revenues fail to materialize.
Sharp Revenue Decline & Negative MarginsA drastic revenue contraction and large negative margins indicate the business remains pre-commercial or commercially unstable. Without durable revenue recovery or secured partner deals, the company faces ongoing loss absorption that undermines predictable cash generation and long-term operational sustainability.
OncoZenge AB News
ONCOZ FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was kr4.51 and its highest was kr10.28 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is kr92.30M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on May 20, 2026. The company reported -kr0.538 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 14,048,068 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -kr0.538 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.735%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in SE:ONCOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Technical Analysis
―
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―